Corcept Therapeutics shares surged after the FDA approved its drug, Lifyorli, for a tough ovarian cancer. This new therapy, combined with chemotherapy, showed a significant survival benefit in trials. The approval, coming early, offers hope for patients whose cancer no longer responds to standard treatments, though some patient groups are excluded.
